Articles tagged with Cancer Cells
Researchers at Baylor Scott & White Research Institute receive NIH funding to investigate the molecular mechanisms that link GERD to Barrett's esophagus and cancer. The team aims to identify strategies to prevent EMT, a process that promotes cancer cell survival.
Researchers at Washington State University discovered a fatty acid called dihomogamma-linolenic acid (DGLA) that can induce ferroptosis in human cancer cells. This iron-dependent type of cell death has been linked to various diseases and may hold potential as a treatment for cancer.
Researchers mapped out immune system of haematological malignancies to identify drug targets and patient groups for immunotherapies. Cytotoxic T and NK cells are abundant in certain subtypes, such as activated B cell-like B cell lymphoma and acute myeloid leukaemia.
The study reveals that Burkholderia pseudomallei infection sets off a series of events that provoke the host's immune system, causing infected cells to self-destruct. The researchers found that abnormal cell fusion stimulates the type 1 interferon signaling pathway, leading to autophagy and cell death.
Researchers at Cold Spring Harbor Laboratory found that interfering with cholesterol storage can stop pancreatic cancer cell growth in mice and lab-grown pancreas models. The study suggests a new strategy for treating deadly disease by targeting an enzyme called SOAT1.
Researchers developed nanoparticles that can deliver a localized cancer treatment by inhibiting tumor growth in mice. The nanoparticles use a specific chemistry to attach a microRNA that prevents cancer cells from producing proteins, leading to cell death.
Scientists study FG-NUPs in normal and colorectal cancer cells, finding altered conformational dynamics in cancer cells. The structure of the central plug is smaller, hindering filamentous features in cancer cells.
Two new studies reveal individual cells maintain internal clocks through a combination of genetic and random mechanisms. These findings suggest that cellular periodicity is influenced by epigenetic control and may hold insights into aging and cancer.
Researchers have successfully engineered T-cells to target a variety of solid-tumor cancer cells in humans and mice using CAR-T therapy. The new approach broadens the potential targets by recognizing proteins with short sugar chains attached, which are often mutated in cancer cells.
Researchers found that a gene's checkpoint mechanism can sometimes allow cells to divide abnormally, leading to worse damage. This discovery has important implications for treating cancer and understanding the inner workings of cells.
Researchers from Immanuel Kant Baltic Federal University discovered how nanoparticles, particularly iron oxide nanocubes and nanoclusters, can selectively target and activate specific genes in liver cancer cells, leading to apoptosis and autophagy. This breakthrough could lead to personalized cancer therapy and diagnostic tools.
A new study finds that chemicals can cause changes in cells to evade the immune system and build resistance to cancer drugs. The team identified specific combinations of mutations that create cancer cells, which could aid doctors in prescribing the most appropriate course of chemotherapy.
Researchers at Lund University successfully blocked sugar uptake in cancer cells using inhibitors, making them more sensitive to chemotherapy. This breakthrough could lead to improved treatment outcomes for patients with acute myeloid leukaemia (AML).
Researchers at Nagoya University have developed a near-infrared photoimmunotherapy (NIR-PIT) treatment targeting podoplanin-positive cells in malignant pleural mesothelioma (MPM). NIR-PIT has shown promise in reducing fluorescence from cancer-tagged cells and demonstrating anti-cancer effects.
Researchers at Memorial Sloan Kettering have engineered CAR T cells to recognize and eliminate senescent cells, which contribute to various debilitating diseases. The uPAR-directed approach has shown promise in mouse models of liver fibrosis and lung cancer, offering hope for new treatments.
Researchers at St. Jude Children's Research Hospital have developed a software system called CICERO that enables better detection of gene fusions in cancers. The system distinguishes fusion events by comparing the cells' RNA sequence with the human genome, identifying potential cancer-causing fusions.
The Pew Scholars Program in Biomedical Sciences supports early-career researchers with four-year funding for foundational research. This year's class of 22 scholars tackles complex questions in biomedicine, including aging differences between males and females, inflammatory disease trajectories, and temperature regulation mechanisms.
UCI researchers have discovered a protein responsible for genetic changes in various cancers and identified potential targets for effective therapy. By monitoring RNA hotspots, the team found that targeting the APOBEC3A protein's activity could disrupt cancer cell vulnerabilities.
A Kazan University research team has developed a novel nanoformulation using biocompatible halloysite nanotubes and bacterial pigment prodigiosin, which selectively disrupts cancer cells without harming healthy ones.
University of California, Berkeley researchers Lydia Sohn and Molly Kozminsky introduce cellular mechanophenotyping to study cancer cell behavior. They aim to measure the mechanical properties of cells to reveal their ability to develop and spread.
A new study found that cancer cells adapt by gobbling up fat molecules from their environment when they can't make their own, potentially rendering treatments ineffective. The research identified a new gene, LUR1, involved in lipid uptake and suggests targeting this process could lead to more effective cancer treatments.
A team of scientists has provided clarity into how new cells remember their identity after cell division. They found that many genes are activated immediately after cell division, acting in a cascade to send critical signals and allow the cell to 'wake up' from its cellular amnesia.
Researchers successfully tagged telomerase with fluorescent molecules, revealing its two-step binding mode to chromosomes. The study also shows how telomerase mutation promotes tumorigenesis, offering a new target for therapeutic strategies.
Researchers found that terahertz radiation can disrupt protein filaments in both aqueous solutions and living cells, but does not kill the cells. This discovery has implications for potential applications in cancer treatment, as well as safety concerns.
Researchers found that cancer cells activate an inflammatory response when in contact with fibroblasts, making it harder for viruses to infect them. By blocking this signaling pathway, oncolytic viruses can more effectively target cancer cells, offering a potential treatment option.
Researchers at Hokkaido University have developed an adenovirus that specifically replicates in and kills cancer cells using RNA-stabilizing elements. The virus, AdARET, was found to be effective against a range of cancer types, including those without a mutated RAS gene.
Researchers found that cancer therapy can trigger the formation of large, aggressive cells with multiple chromosomes. A scientist is now developing a drug to prevent or treat these rogue cells, which can lead to cancer recurrence.
Researchers at CSIC pioneer the use of whole living cells in dynamic combinatorial chemistry systems to discover new bioactive molecules. This methodology has great potential in rapidly identifying new molecules with potential biological activity, and could lead to faster discovery of bioactive compounds.
Researchers have confirmed biological hallmarks of survival in tumor cells and identified two processes linked to high-grade serous carcinoma. Proteomics analysis reveals details about protein communication and function in cancerous cells, providing insights into the 'broken' machinery behind ovarian cancer.
A newly identified biomarker could help scientists pinpoint which cancers are vulnerable to treatment with biguanides, a common class of medications used to control blood sugar in Type 2 diabetes. The biomarker is linked to the gene MYC and has been found to be regulated by microRNAs that target certain cancer cells.
A new imaging method detects metabolic and structural changes in cervical epithelial cells using intrinsic fluorescence, enabling early-stage bedside diagnosis. This non-invasive approach opens up a routine monitoring strategy for patients at high risk of cervical cancer.
Researchers created a way to study and map intercellular signaling to understand cell movement mechanisms in healthy cells and disease states like cancer metastasis. The new tool uses microscopy tools and mathematical methods to visualize protein activity and quantify regulation of signaling networks.
A new study from Scripps Research reveals that the protein YAP plays a dual role in regulating cell growth, both promoting and inhibiting proliferation. This finding has significant implications for understanding cancer behavior and developing targeted therapies.
Researchers at IST Austria found that actin flows from front to tail, driving cell movement, and can couple with environment without integrins, enabling flexible crawling through tissues. This 'off-road' mode of locomotion allows cells to migrate efficiently in various environments.
Researchers at Université catholique de Louvain discovered that cancer cells can deactivate the CD166 'Velcro' protein on their surface, allowing them to migrate more easily and form metastases. This fundamental mechanism may lead to the development of new solutions to block metastasis and slow down cancer progression.
A research team at Pohang University of Science & Technology has developed an integrative cancer therapy using adoptive natural killer cell therapy and chemotherapy. The new method enhances the effectiveness of cell therapy in treating solid cancers by selectively releasing anticancer drugs, reducing side effects.
A new study has identified a crucial role for the protein RTEL1 in the survival of cancer cells, with potential implications for treating various types of cancer. Researchers found that RTEL1 prevents damaging clashes between DNA replication and transcription processes, and promotes a process called MiDAS, which is common in cancer cells.
Scientists at the University of Oxford have discovered a new way for T cells to attack cells infected by viruses or cancer. Supramolecular attack particles (SMAPs), released from cytotoxic T lymphocytes, can autonomously kill targeted cells, providing a complementary mechanism of cytotoxicity.
Researchers are teaming up to understand why critical nerve cells continue to die after spinal cord injuries and aim to develop more effective treatments by enhancing or limiting the immune response. They'll use a new probe developed by one scientist to track dead cells as they're swallowed up by immune cells.
Researchers from Skoltech have made significant progress in understanding the apoptotic program, a crucial process for removing unneeded or abnormal cells. The study has identified key proteins involved in this process, which could lead to new therapeutic targets for treating cancer.
Researchers at TUM have discovered a novel mechanism that inhibits cancer-specific immune responses, leading to the development of new immunotherapies. The discovery identifies a suppressive metabolite from glucose metabolism as a key factor in limiting cancer immunity.
Hyperdiploid B-ALL, the most common subtype of pediatric leukemia, arises from a malfunctioning Condensin complex, Aurora B kinase, and mitotic checkpoint in cell division. Researchers have unveiled the molecular mechanisms underlying HyperD-ALL origin and progression.
Scientists have developed a multi-functional graphene-based nanomedicine that targets cancer cells with enhanced anticancer activity. The material, which combines three types of molecules for improved tumor targeting and drug delivery, shows promise for future biomedical applications.
Bayreuth geneticists have discovered a natural protective mechanism that leads to the programmed death of potentially diseased cells. The separase enzyme plays a central role in this process and can be re-purposed to induce apoptosis in cancer cells.
The study found that combinations of paclitaxel (PAC) and withaferin A (WFA) are highly synergistic against human non-small cell lung cancer cells, showing greater sensitivity than either treatment alone. WFA was active against PAC-sensitive and PAC-resistant NSCLC cells, demonstrating its potential therapeutic efficacy.
Researchers found that pancreatic cancer cells use autophagy to degrade MHC-I proteins, making them resistant to immunotherapies. Blocking autophagy or using drugs like chloroquine enhances MHC-I expression on the surface of cancer cells, increasing their susceptibility to immunotherapy.
A study has identified frequent cancer-driving mutations in healthy human endometrium, suggesting that these events may occur early in life. These mutant stem cells can accumulate further driver mutations over time, leading to invasive cancer years or even decades later.
Researchers at Salk Institute discover formation of tuft cells during pancreatitis, which secrete IL-25 to promote immune response. The finding may lead to development of new treatments for pancreatitis and pancreatic cancer.
Researchers at Skoltech and MIT have developed a new combinatorial therapy for liver cancer using a siRNA approach coupled with lipid nanoparticle technology. This treatment caused a significant decrease in tumor load in a mouse model of hepatocellular carcinoma.
Researchers at Penn State have directly observed functional metabolons involved in generating purines, the most abundant cellular metabolites. The findings suggest that enzymes are not haphazardly located throughout cells but instead occur in discrete clusters, or metabolons, that carry out specific metabolic pathways.
A new study led by UT Southwestern scientists suggests that tumors can manipulate the cell death signaling pathway to evade an immune response after radiation. By blocking this pathway, researchers found that cancer cells can secrete more interferons, which triggers a tumor-fighting immune response.
The VRAC ion channel transports the messenger substance cGAMP from cell to cell, strengthening the immune response to DNA virus infections. This discovery could also have implications for cancer treatment and new strategies against DNA viruses.
Researchers at the University of Freiburg have discovered that cancer-causing mutations in the KRAS gene lead to inflammation and slow down tumor growth. The study, led by Prof. Dr. Robert Zeiser, shows that K-Ras plays a dual role in both cancer development and immune response.
A team of NYU Abu Dhabi researchers have developed a new, one-pot synthetic approach to obtain water-stable and ready-to-use gold nanoparticles. These nanoparticles can be heated with a simple green laser, improving their ability to penetrate and destroy malignant cells through hyperthermia while releasing chemotherapeutic drugs.
A team of researchers from RIKEN has developed a new single-cell RNA sequencing method called Quartz-seq2 that outperforms other methods in terms of accuracy and reproducibility. The method was benchmarked against 13 different methods using a set of approximately 3,000 cells, and it scored highest on the benchmark.
Researchers at the Medical University of South Carolina have discovered a natural product, manzamine A, that exhibits anti-cancer properties in cervical cancer cells. The compound stops cell growth and causes some cells to die, with potential applications for treatment and development.
A new study found that mother cells decide whether their daughter cells will divide based on environmental growth factors. The discovery could lead to longer windows for cancer drug therapies.
Scientists have engineered T-cells to target multiple sites on leukemia cells, offering a more effective treatment for resistant acute lymphoblastic leukemia. The new CAR-T therapy, TriCAR T-cells, targeting CD-19/20/22, demonstrate improved efficacy compared to single-antigen therapies.
A virtual computational cell was built to predict cancer metastasis by analyzing the interaction of numerous molecules and signals within the tumor environment. The research found that hybrid cancer cells can be targeted using specific molecular signals and extracellular matrix proteins, offering new therapeutic strategies against cancer.
Researchers at MD Anderson Cancer Center propose using glucose transporter inhibitors to treat tumors with high expression of the SLC7A11 amino acid transporter. This approach targets cancer cells' dependency on glucose for survival, selectively killing 'addicted' cells.